These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 22173845)

  • 1. Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms.
    Raz I; Eldor R
    Diabetes Metab Res Rev; 2012 May; 28(4):321-4. PubMed ID: 22173845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editors' note to Raz and Eldor's commentary "Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms". Diabetes Metab Res Rev 2012.
    Roth J; Pozzilli P
    Diabetes Metab Res Rev; 2012 May; 28(4):325. PubMed ID: 22576779
    [No Abstract]   [Full Text] [Related]  

  • 3. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
    Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
    Pinelli NR; Cha R; Brown MB; Jaber LA
    Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis.
    Vanderpoel DR; Hussein MA; Watson-Heidari T; Perry A
    Clin Ther; 2004 Dec; 26(12):2066-75. PubMed ID: 15823770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promising new approaches.
    Reasner CA
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2011 Feb; (170):31-46. PubMed ID: 21323811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with glynclamide, a new hypoglycaemic agent.
    Burns FH
    Med J Aust; 1969 Aug; 2(9):436-9. PubMed ID: 4898056
    [No Abstract]   [Full Text] [Related]  

  • 9. New ways of insulin delivery.
    Heinemann L
    Int J Clin Pract Suppl; 2010 Feb; (166):29-40. PubMed ID: 20377662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffusion into use of exenatide for glucose control in diabetes mellitus: a retrospective cohort study of a new therapy.
    Segal JB; Dy SM; Millman EA; Herbert R; Bass EB; Wu A
    Clin Ther; 2007 Aug; 29(8):1784-94. PubMed ID: 17919559
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translating comparative effectiveness into practice: the case of diabetes medications.
    Shah ND; Mullan RJ; Breslin M; Yawn BP; Ting HH; Montori VM
    Med Care; 2010 Jun; 48(6 Suppl):S153-8. PubMed ID: 20473211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adherence to oral antidiabetic agents with pioglitazone and metformin: comparison of fixed-dose combination therapy with monotherapy and loose-dose combination therapy.
    Barner JC
    Clin Ther; 2011 Sep; 33(9):1281-8. PubMed ID: 21840054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The rough road for rosiglitazone.
    Goldfine AB
    Curr Opin Endocrinol Diabetes Obes; 2008 Apr; 15(2):113-7. PubMed ID: 18316944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.
    Levin P; Wei W; Wang L; Pan C; Douglas D; Baser O
    Curr Med Res Opin; 2012 Mar; 28(3):439-46. PubMed ID: 22216894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparisons of rosiglitazone versus pioglitazone monotherapy introduction and associated health care utilization in Medicaid-enrolled patients with type 2 diabetes mellitus.
    Balkrishnan R; Arondekar BV; Camacho FT; Shenolikar RA; Horblyuk R; Anderson RT
    Clin Ther; 2007 Jun; 29(6 Pt 1):1306-15. PubMed ID: 18036392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reevaluating goals of insulin therapy: perspectives from large clinical trials.
    Riddle MC; Yuen KC
    Endocrinol Metab Clin North Am; 2012 Mar; 41(1):41-56. PubMed ID: 22575406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular risk of rosiglitazone: another perspective.
    Waksman JC
    J Pharm Pharmacol; 2008 Dec; 60(12):1573-82. PubMed ID: 19000361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone.
    Bailey CJ; Green BD; Flatt PR
    Expert Opin Investig Drugs; 2010 Aug; 19(8):1017-25. PubMed ID: 20629618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of exenatide, pen insulin, and vial insulin on patient outcomes: a retrospective database analysis of persistence and first-year costs in a commercially insured population.
    Rashid N; McCombs JS; Schwartz E
    Clin Ther; 2012 May; 34(5):1145-58. PubMed ID: 22464691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.